Peter Kellogg
Director of Finance/CFO at RECEPTOS INC
Net worth: 34 440 $ as of 2024-03-30
Peter Kellogg active positions
Companies | Position | Start | End |
---|---|---|---|
RECEPTOS INC | Director of Finance/CFO | - | - |
JUNO THERAPEUTICS INC | Director/Board Member | - | - |
IDORSIA LTD | Director/Board Member | 2021-05-11 | - |
ALNYLAM PHARMACEUTICALS, INC. | Director/Board Member | 2023-03-06 | - |
Independent Dir/Board Member | 2023-03-06 | - | |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Director/Board Member | - | - |
Career history of Peter Kellogg
Former positions of Peter Kellogg
Companies | Position | Start | End |
---|---|---|---|
YIELD10 BIOSCIENCE, INC. | Director/Board Member | 2007-03-29 | 2020-02-10 |
Independent Dir/Board Member | 2011-11-07 | 2020-02-10 | |
CELGENE | Comptroller/Controller/Auditor | - | 2018-07-31 |
Director of Finance/CFO | 2014-07-31 | 2018-07-31 | |
Corporate Officer/Principal | 2018-07-31 | 2018-12-31 | |
MERCK & CO., INC. | Director of Finance/CFO | 2007-07-31 | 2014-04-22 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Director of Finance/CFO | 2009-11-02 | 2009-11-02 |
░░░░░ ░░░░░ ░ ░░░░░ ░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ ░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░░ ░░░░░░ ░░░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Peter Kellogg
Princeton University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
United States | 20 |
Switzerland | 3 |
Operational
Director of Finance/CFO | 9 |
Corporate Officer/Principal | 6 |
Director/Board Member | 5 |
Sectoral
Health Technology | 13 |
Consumer Non-Durables | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 6 |
---|---|
MERCK & CO., INC. | Health Technology |
PEPSICO, INC. | Consumer Non-Durables |
BIOGEN INC. | Health Technology |
YIELD10 BIOSCIENCE, INC. | Process Industries |
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
IDORSIA LTD | Health Technology |
Private companies | 13 |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Pepsi-Cola International Ltd. (New York)
Pepsi-Cola International Ltd. (New York) Beverages: Non-AlcoholicConsumer Non-Durables Part of PepsiCo, Inc., Pepsi-Cola International Ltd. is a private company based in Purchase, NY. The company makes soft drinks and snack foods. | Consumer Non-Durables |
Pepsi-Cola North America
Pepsi-Cola North America Beverages: Non-AlcoholicConsumer Non-Durables Pepsi-Cola North America manufactures and markets beverage products. It offers soft drinks, bottled waters, iced teas, juices, and sports drinks. The company is headquartered in Purchase, NY | Consumer Non-Durables |
PepsiCo Food International
PepsiCo Food International Beverages: Non-AlcoholicConsumer Non-Durables Part of PepsiCo, Inc., PepsiCo Food International is a carbonated beverage company. The private company is based in Purchase, NY. | Consumer Non-Durables |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Frito-Lay International | |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Health Technology |
- Stock Market
- Insiders
- Peter Kellogg
- Experience